The essential role of IGF-I: Lessons from the long-term study and treatment of children and adults with Laron syndrome

Journal of Clinical Endocrinology and Metabolism

Volumn 84, Issue 12, 1999, Pages 4397-4404

  Laron, Zvi ^a,b  

^a SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOMEDIN C;

ADOLESCENT; ADULT; CHILD; CLINICAL ARTICLE; DRUG EFFECT; DRUG MECHANISM; EDEMA; GENOTYPE; GROWTH STIMULATION; HUMAN; HYPERANDROGENISM; HYPOGLYCEMIA; LARON SYNDROME; PHENOTYPE; PRESCHOOL CHILD; PRIORITY JOURNAL; REVIEW; SCHOOL CHILD; TREATMENT OUTCOME;

EID: 0033305597     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jcem.84.12.6255     Document Type: Review

References (75)

1. Genetic pituitary dwarfism with high serum concentration of growth hormone. A new inborn error of metabolism?
2. Pituitary dwarfism with high serum levels of growth hormone
3. Administration of growth hormone to patients with familial dwarfism with high plasma immunoreactive growth hormone. Measurement of sulfation factor, metabolic, and linear growth responses
4. Prismatic cases: Laron syndrome (primary growth hormone resistance). From patient to laboratory to patient
5. Laron type dwarfism (hereditary somatomedin deficiency): A review
6. The little women of Loja: Growth hormone receptor deficiency in an inbred population of Southern Ecuador
7. Laron syndrome: Primary growth hormone resistance
8. Lessons from Laron syndrome (LS) 1966-1992
9. Classification of growth hormone insensitivity syndrome
10. Short stature caused by a mutant growth hormone
11. Characterization of the human growth hormone receptor gene and demonstration of a partial gene deletion in two patients with Laron type dwarfism
12. Molecular basis of inherited growth hormone resistance in childhood
13. Nine novel growth hormone receptor gene mutations in patients with Laron syndrome
14. Growth hormone (GH) insensitivity syndrome with high serum GH-binding protein levels caused by a heterozygous splice site mutation of the GH receptor gene producing a lack of intracellular domain
15. A novel mutation affecting the interdomain link region of the growth hormone receptor in a Vietnamese girl, and response to long-term treatment with recombinant human insulin-like growth factor-I and luteinizing hormone-releasing hormone analogue
16. Intronic mutation in the growth hormone (GH) receptor gene from a girl with Laron syndrome and extremely high serum GH binding protein: Extended phenotypic study in a very large pedigree
17. A dominant-negative mutation of the growth hormone receptor causes familial short stature
18. Intrauterine growth retardation and postnatal growth failure associated with deletion of the insulin-like factor I gene
19. Pseudopituitary dwarfism due to resistance to somatomedin: A new syndrome
20. An infant with deletion of the distal long arm of chromosome 15 (q26,1→qter) and loss of insulin-like growth factor I receptor gene
21. In vitro and in vivo responses to short term recombinant human insulin-like growth factor-I (IGF-I) in a severely growth retarded girl with ring chromosome 15 and deletion of a single allele for the IGFI receptor gene
22. Effects of an IGFI gene null mutation on mouse reproduction
23. A mammalian model for Laron syndrome produced by targeted disruption of the mouse growth hormone receptor/binding protein gene (the Laron mouse)
24. Is the Laron mouse an accurate model of Laron syndrome?
25. Natural history of the classical form of primary growth hormone (GH) resistance (Laron syndrome)
26. Three year IGF-I treatment of children with Laron syndrome
27. IGF-I treatment of adult patients with Laron syndrome: Preliminary results
28. Are there direct, non-IGF-I mediated effects of hGH
29. Girls with Laron syndrome having positive growth hormone binding protein (GHBP) are less retarded in height than those lacking GHBP
30. Phenotype: Genotype relationships in growth hormone insensitivity syndrome
31. Laron syndrome: From description to therapy
32. Clinical features and endocrine status in patients with growth hormone insensitivity (Laron syndrome)
33. Growth hormone receptor deficiency in Educador: Clinical and biochemical phenotype in two populations
34. Skull changes in pituitary dwarfism and the syndrome of familial dwarfism with high plasma immumoreactive growth hormone. A roentgenological study
35. Laron syndrome: A unique model of IGF-I deficiency. History, clinical and biochemical characteristics
36. Cognitive and psychosocial functioning of young adults with Laron syndrome
37. Penis and testicular size in patients with growth hormone insufficiency
38. Puberty in Laron type dwarfism
39. Body fat in Laron syndrome patients: Effect of insulin-like growth factor treatment
40. Hypoglycemia due to hormone deficiencies
41. Insulin resistance in Laron syndrome [primary insulin-like growth factor-I (IGF-I) deficiency] and effect of IGF-I replacement therapy
42. Carbohydrate metabolism in the syndrome of familial dwarfism and high plasma immunoreactive growth hormone (Laron type dwarfism)
43. Muscle force and endurance in untreated and human growth hormone or insulin-like growth factor-I treated patients with growth hormone deficiency or Laron syndrome
44. Chemical synthesis, cloning and expression of genes for human somatomedin C (insulin like growth factor I) and 59Val somatomedin C
45. Short term metabolic effects of recombinant human insulin like growth factor in healthy adults
46. Repeated s.c. administration of recombinant insulin like growth factor I (IGF-I) to human patients for 7 days
47. Elimination characteristics of intravenously administered rIGF-I in Laron type dwarfs (LTD)
48. Effects of acute administration of insulin like growth factor I in patients with Laron-type dwarfism
49. Intravenous administration of recombinant IGF-I lowers serum GHRH and TSH
50. Differential effect of insulin-like growth factor I (IGF-I) and growth hormone (GH) on hypothalamic regulation of GH secretion in the rat
51. Serum prolactin in patients with Laron type dwarfism (LTD): Effect of insulin like growth factor I (IGF-I)
52. Development of hyperandrogenism during treatment with insulin-like growth factor-I (IGF-I) in female patients with Laron syndrome
53. Effect of insulin-like growth factor-I treatment on serum androgens and testicular and penile size in males with Laron syndrome (primary growth hormone resistance)
54. Comparison between the growth promoting effects of IGF-I and GH in the early years
55. A dual effector theory of growth hormone action
56. Mechanism of the stimulatory effects of growth hormone on longitudinal bone growth
57. Insulin-like growth factor I improves height in growth hormone insensitivity: Two years' results
58. Prolonged treatment with recombinant insulin-like growth factor-I in children with growth hormone insensitivity syndrome: A Clinical Research Center study
59. Two year treatment of growth hormone (GH) receptor deficiency with recombinant insulin-like growth factor-I in 22 children; Comparison of two dosage levels and to GH treated GH deficiency
60. Factors predicting the response to growth hormone (GH) therapy in prepubertal children with GH deficiency
61. Growth curves for Laron syndrome
62. Hyperandrogenism induced by insulin-like growth factor-I (IGF-I) treatment of two girls with Laron syndrome
63. Serum insulin-like growth factor-I (IGF-I) levels during long-term IGF-I treatment of children and adults with primary GH resistance (Laron syndrome)
64. Long-term treatment of Laron type dwarfs with insulin-like growth factor I increases serum insulin-like growth factor-binding protein 3 in the absence of growth hormone activity
65. Renal function in Laron syndrome patients treated by insulin-like growth factor- I
66. Insulin-like growth factor-I raises serum procollagen levels in children and adults with Laron syndrome
67. Insulin-like growth factor I lowers serum lipoprotein(a) during long-term treatment of patients with Laron syndrome
68. Growth hormone increases and insulin-like growth factor-I decreases circulating lipoprotein(a)
69. Effects of the infusion of insulin-like growth factor-I in a child with growth hormone insensitivity syndrome (Laron dwarfism)
70. Effect of human growth hormone therapy on head circumference in children with hypopituitarism
71. Effects of insulin-like growth factor-I on linear growth, head circumference and body fat in patients with Laron-type dwarfism
72. Echocardiographic dimensions, and function in adults with primary growth hormone resistance (Laron Syndrome)
73. Adjustment and rehabilitation problems of children and adolescents with growth retardation. I. Familial dwarfism with high plasma immunoreactive human growth hormone
74. Somatomedin-1 (recombinant insulin-like growth factor-I). Clinical pharmacology and potential treatment of endocrine and metabolic disorders
75. Clinical use of insulin-like growth factor-I - Yes or no?